跳至主要内容
临床试验/EUCTR2015-005303-91-IT
EUCTR2015-005303-91-IT进行中(未招募)1 期

Clinical Trial of pharmacokinetics of calcifediol (25OHD3) in women with postmenopausal osteoporosis - VIT_D_2015

AZIENDA OSPEDALIERA UNIVERSITARIA SENESE0 个研究点目标入组 50 人开始时间: 2020年11月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Post-menopausal women (amenorrea for at least 5 years).
  • Age between 55 and 70 years
  • Lumbar or Femoral T-score (DXA) = - 2.5 DS
  • Serum levels of 25(OH)D3 between 10 and 20 ng/ml
  • Informed Consent signed
  • Willingness and capacity to adhere to study protocol.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • Femoral T-score (DXA) = -3.0 DS
  • History of fragility fractures
  • Osteomalacia or Paget disease of bone
  • Secondary Osteoporosis (primary or secondary hyperparathyroidism, Cushings disease,etc)
  • Treatment with oestrogen, drugs for osteoporosis or drugs known to interfere with bone metabolism (glucocorticoids, anticonvulsants, heparin, antiretrovirals etc)
  • Diabetes Mellitus Type 1 and 2
  • Neoplastic Diseases
  • BMI < 18 or >29.9 kg/m2
  • Treatment with calcifediol, calcitriol or colecalciferol in the previous 2 months
  • Mental and cognitive disorders
  • Inability or unwillingness to adhere to the study protocol
  • Refuse to sign the informed Consent.

研究者

发起方
AZIENDA OSPEDALIERA UNIVERSITARIA SENESE

相似试验